Vericel (VCEL) Common Equity (2010 - 2026)
Vericel (VCEL) posted Common Equity of $370.0 million for Q2 2026, up 3.88% sequentially from $356.2 million in Q1 2026, and up 20.61% YoY from $306.8 million in Q2 2025.
Vericel (VCEL) Common Equity (2010 - 2026) Analysis & Trends
Vericel has reported Common Equity for 17 years, with the latest figure at $370.0 million in Q2 2026.
- Quarterly Common Equity rose 20.61% year-over-year to $370.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $370.0 million (up 20.61% YoY) and the FY2025 annual result came in at $354.6 million, up 21.47% from the prior year.
- Common Equity climbed to $370.0 million in Q2 2026 per VCEL's latest filing, from $356.2 million in the prior quarter.
- Over five years, Common Equity peaked at $370.0 million in Q2 2026 and troughed at $172.5 million in Q1 2022.
- A 5-year average of $254.0 million and a median of $238.4 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity grew 12.46% in 2023, then grew 29.22% in 2024.
- Over 5 years, Common Equity stood at $192.3 million in 2022, then climbed by 17.52% to $226.0 million in 2023, then gained by 29.22% to $292.0 million in 2024, then rose by 21.47% to $354.6 million in 2025, then advanced by 4.34% to $370.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $370.0 million, $356.2 million, and $354.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 370.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 370.04 Mn |
| Mar 31, 2026 | 356.23 Mn |
| Dec 31, 2025 | 354.64 Mn |
| Sep 30, 2025 | 321.86 Mn |
| Jun 30, 2025 | 306.81 Mn |
| Mar 31, 2025 | 295.49 Mn |
| Dec 31, 2024 | 291.97 Mn |
| Sep 30, 2024 | 257.47 Mn |
| Jun 30, 2024 | 242.98 Mn |
| Mar 31, 2024 | 233.90 Mn |
| Dec 31, 2023 | 225.95 Mn |
| Sep 30, 2023 | 204.38 Mn |
| Jun 30, 2023 | 198.93 Mn |
| Mar 31, 2023 | 193.98 Mn |
| Dec 31, 2022 | 192.27 Mn |
| Sep 30, 2022 | 177.84 Mn |
| Jun 30, 2022 | 174.82 Mn |
| Mar 31, 2022 | 172.49 Mn |
| Dec 31, 2021 | 170.46 Mn |
| Sep 30, 2021 | 156.78 Mn |